Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Recombinant human N-acetylgalactosamine-6-sulfatase

EU orphan designation number: EU/3/09/657   
Active ingredient: Recombinant human N-acetylgalactosamine-6-sulfatase
Indication: Treatment of mucopolysaccharidosis, type IVA (Morquio A Syndrome)
Sponsor: BioMarin Europe Ltd
164 Shaftesbury Avenue, London WC2H 8HL, United Kingdom
EU Centralised marketing authorisation: A centralised EU marketing authorisation has been obtained under the name Vimizim on 28/04/2014 with the number EU/1/14/914

   Public summary of scientific opinion     EPAR

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
30/07/2009 Centralised Orphan - Designation EMEA/OD/017/09 (2009)6074 of 24/07/2009